Systems-based discovery advances drug development

S. A. Waldman, Andre Terzic

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Drug development expenditures continue to escalate, in part reflecting inefficiencies in current drug discovery paradigms. Traditional drug discovery has been dichotomous, focusing either on phenotypic effects of distinct agents in biological systems, without knowledge of respective targets, or on target-based activities of specific molecules in cell-free assays. Driven by advances in biology, engineering, and informatics, new paradigms integrate phenotypic with target-based algorithms into comprehensive, systems-level approaches offering value-added strategies for optimized drug discovery.

Original languageEnglish (US)
Pages (from-to)285-287
Number of pages3
JournalClinical Pharmacology and Therapeutics
Volume93
Issue number4
DOIs
StatePublished - Apr 2013

Fingerprint

Drug Discovery
Informatics
Health Expenditures
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Systems-based discovery advances drug development. / Waldman, S. A.; Terzic, Andre.

In: Clinical Pharmacology and Therapeutics, Vol. 93, No. 4, 04.2013, p. 285-287.

Research output: Contribution to journalArticle

@article{3ffc8bb75bac4521b6b955a6237c2f04,
title = "Systems-based discovery advances drug development",
abstract = "Drug development expenditures continue to escalate, in part reflecting inefficiencies in current drug discovery paradigms. Traditional drug discovery has been dichotomous, focusing either on phenotypic effects of distinct agents in biological systems, without knowledge of respective targets, or on target-based activities of specific molecules in cell-free assays. Driven by advances in biology, engineering, and informatics, new paradigms integrate phenotypic with target-based algorithms into comprehensive, systems-level approaches offering value-added strategies for optimized drug discovery.",
author = "Waldman, {S. A.} and Andre Terzic",
year = "2013",
month = "4",
doi = "10.1038/clpt.2013.21",
language = "English (US)",
volume = "93",
pages = "285--287",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Systems-based discovery advances drug development

AU - Waldman, S. A.

AU - Terzic, Andre

PY - 2013/4

Y1 - 2013/4

N2 - Drug development expenditures continue to escalate, in part reflecting inefficiencies in current drug discovery paradigms. Traditional drug discovery has been dichotomous, focusing either on phenotypic effects of distinct agents in biological systems, without knowledge of respective targets, or on target-based activities of specific molecules in cell-free assays. Driven by advances in biology, engineering, and informatics, new paradigms integrate phenotypic with target-based algorithms into comprehensive, systems-level approaches offering value-added strategies for optimized drug discovery.

AB - Drug development expenditures continue to escalate, in part reflecting inefficiencies in current drug discovery paradigms. Traditional drug discovery has been dichotomous, focusing either on phenotypic effects of distinct agents in biological systems, without knowledge of respective targets, or on target-based activities of specific molecules in cell-free assays. Driven by advances in biology, engineering, and informatics, new paradigms integrate phenotypic with target-based algorithms into comprehensive, systems-level approaches offering value-added strategies for optimized drug discovery.

UR - http://www.scopus.com/inward/record.url?scp=84875471298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875471298&partnerID=8YFLogxK

U2 - 10.1038/clpt.2013.21

DO - 10.1038/clpt.2013.21

M3 - Article

VL - 93

SP - 285

EP - 287

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 4

ER -